Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting

Digestive Diseases and Sciences

Volumn 59, Issue 12, 2014, Pages 3043-3052

  Price, Jennifer C ^a   Murphy, Rosemary C ^b   Shvachko, Valentina A ^b   Pauly, Mary Pat ^b   Manos, M Michele ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

Antiviral therapy; Boceprevir; DAA; HCV; Telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; VIRUS RNA;

ACUTE PANCREATITIS; ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; APLASTIC ANEMIA; ARTICLE; DATA BASE; DECOMPENSATED LIVER CIRRHOSIS; DRESS SYNDROME; DRUG EFFICACY; EXPERIENCE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL RECORD; SEPSIS; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; YOUNG ADULT;

EID: 84912532123     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3294-0     Document Type: Article

References (31)

1. http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed 17 Jan 2014.
2. Kim WR, Stock PG, Smith JM, et al. OPTN/SRTR 2011 annual data report: liver. Am J Transpl. 2013;13:73–102.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
4. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
5. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
6. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
7. Jacobson IM, Pawlotsky JM, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis. C J Viral Hepat. 2012;19:1–26.
8. Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One. 2013;8:e55285.
9. Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Fernandez N. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients Hepatology. 2010;51:2231; author reply 2231–2232.
10. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46:37–47.
11. Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm. 2013;19:438–447.
12. Gordon N. Similarity of the adult Kaiser Permanente membership in northern California to the insured and general population in northern California: statistics from the 2007 California Health Interview Survey. Internal Report: Kaiser Permanente Division of Research. 2012.
13. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703–710.
14. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:e1452.
15. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol. 2012;84:1744–1750.
16. Kwo PY. Phase III results in Genotype 1 naive patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int. 2012;32:39–43.
17. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143:e601–e605.
18. Hezode C, Fontaine H, Dorival C et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)—NCT01514890. J Hepatol. 2013;59:434–441.
19. Saxena V, Manos MM, Yee H et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis Aliment Pharmacol Ther (in press).
20. INCIVEK [package insert]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; 2011.
21. VICTRELIS [package insert]. Whitehouse Station, NJ: Schering Corporation, a subsidiary of Merck & Co, INC; 2011.
22. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–1024.
23. Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection, based on a nationwide study of veterans Clin Gastroenterol Hepatol. 2014;12:1371–1380.
24. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther. 2014;39:93–103.
25. Wehmeyer MH, Eissing F, Jordan S, et al. Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection. BMC Gastroenterol. 2014;14:87.
26. Maasoumy B, Port K, Deterding K, et al. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. Eur J Gastroenterol Hepatol. 2014;26:836–845.
27. Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system. J Manag Care Pharm. 2014;20:533–540.
28. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
29. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146:e436.
30. Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin for the treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase 3 trial. J Hepatol. 2013, abstract 1413.
31. Shiffman ML, Benhamou Y. HCV F1/F2 patients: treat now or continue to wait. Liver Int. 2014;34:79–84.